- Home
- RARE vs RCUS Comparison
RARE vs RCUS Comparison
Compare RARE & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RARE | RCUS |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | United States | United States |
| Employees | N/A | 674 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.9B |
| IPO Year | 2014 | 2018 |
Fundamental Metrics
Financial Performance| Metric | RARE | RCUS |
|---|---|---|
| Price | $34.13 | $22.71 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 8 |
| Target Price | ★ $85.20 | $29.38 |
| AVG Volume (30 Days) | 1.6M | ★ 2.4M |
| Earning Date | 02-12-2026 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $630,598,000.00 | $240,000,000.00 |
| Revenue This Year | $19.09 | N/A |
| Revenue Next Year | $20.62 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 20.63 | N/A |
| 52 Week Low | $25.81 | $6.50 |
| 52 Week High | $46.50 | $26.40 |
Technical Indicators
Market Signals| Indicator | RARE | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 49.54 | 50.10 |
| Support Level | $32.64 | $21.80 |
| Resistance Level | $35.12 | $22.70 |
| Average True Range (ATR) | 1.44 | 1.27 |
| MACD | -0.27 | -0.45 |
| Stochastic Oscillator | 22.07 | 38.18 |
Price Performance
Historical ComparisonAbout RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.